Latest News for: rigel
Edit
Opinion: How an accessory dwelling could turn into a 20-story tower in Berkeley
East Bay Times 17 Dec 2025
Edit
The Daily Journal - San Mateo
15 Dec 2025
How an accessory dwelling could turn into a 20-story tower
At first the plan for the property a block from UC Berkeley was modest. build a two-unit accessory dwelling behind a pair of small apartment buildings ... .
Edit
Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition (Form 8-K) (Rigel Pharmaceuticals Inc)
Public Technologies 10 Dec 2025
SOUTH SAN FRANCISCO, Calif., December 7, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc ... About Rigel. Rigel Pharmaceuticals, Inc ... Founded in 1996, Rigel is based in South San Francisco, California ... Rigel Pharmaceuticals Inc.
Edit
Lebanon Express
08 Dec 2025
Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with ...
R289 continues to be generally well tolerated and at ...
Edit
Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition (Rigel Pharmaceuticals Inc)
Public Technologies 07 Dec 2025
December 7, 2025 Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition ... 7, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc ... About Rigel ... ir@rigel.com.
Edit
December 2025 (Rigel Pharmaceuticals Inc)
Public Technologies 07 Dec 2025
) Corporate Presentation. December 7, 2025. Growing Our Hematology and Oncology Business. Commercial Execution. ITP ... Expand olutasidenib beyond mIDH1 R/R AML through strategic collaborations and potential Rigel-led studies ... 1 ... FDA ... Rigel Pharmaceuticals Inc.
Edit
Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition
PR Newswire 07 Dec 2025
7, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq ... Rigel's open-label Phase 1b study of R289 is evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy in patients with R/R lower-risk MDS (NCT05308264).
Edit
Statement of Changes in Beneficial Ownership (Form 4) (Rigel Resource Acquisition Corp)
Public Technologies 04 Dec 2025
Rigel Resource Acquisition Corp ... (1) These Class A Ordinary Shares of Rigel Resource Acquisition Corp (the "Issuer") reported as disposed were redeemed by the ... Rigel Resource Acquisition Corp.
Edit
Missoulian
27 Nov 2025
Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference
26, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq.
Edit
The Porterville Recorder
18 Nov 2025
Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 ...
Olutasidenib continued to demonstrate durable efficacy and a ...
Edit
Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology (Rigel Pharmaceuticals Inc)
Public Technologies 17 Nov 2025
November 17, 2025 Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology ... 17, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc ... About Rigel.
Edit
Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology
PR Newswire 17 Nov 2025
17, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc ... "This long-term final analysis of olutasidenib reinforces the potential for olutasidenib in mIDH1 AML," said Lisa Rojkjaer, M.D, Rigel's chief medical officer ... About Rigel Rigel Pharmaceuticals, Inc.
Edit
Termination Notice (Form 15-12G) (Rigel Resource Acquisition Corp)
Public Technologies 13 Nov 2025
Rigel Resource Acquisition Corp ... Pursuant to the requirements of the Securities Exchange Act of 1934 Rigel Resource Acquisition Corp has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.
Edit
Rigel to Present at the Jefferies Global Healthcare Conference in London
PR Newswire 12 Nov 2025
12, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc ... To access the live webcast or archived recording, visit the Investor Relations section of the company's website at www.rigel.com ... About Rigel Rigel Pharmaceuticals, Inc.
- 1
- 2
- Next page »